Postprandial Dynamics of Plasma Glucose, Insulin, and Glucagon in Patients with Type 2 Diabetes Treated with Saxagliptin Plus Dapagliflozin Add-On to Metformin Therapy-Reference-Cited by-同舟云学术

Postprandial Dynamics of Plasma Glucose, Insulin, and Glucagon in Patients with Type 2 Diabetes Treated with Saxagliptin Plus Dapagliflozin Add-On to Metformin Therapy

Published:2014-11 Issue:11 Volume:20 Page:1187-1197
ISSN:1530-891X
Container-title:Endocrine Practice
language:en
Short-container-title:Endocrine Practice

Author:

Hansen Lars,Iqbal Nayyar,Ekholm Ella,Cook William,Hirshberg Boaz

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism

Link

http://aace.metapress.com/index/N51R81X7506U0413.pdf

Reference23 articles.

1. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized, double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin;Rosenstock;Diabetes Care.,2014

2. The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet.,2006

3. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes;DeFronzo;Diabetes Care.,2013

4. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial;Ferrannini;Diabetes Care.,2010

5. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial;Frederich;Diabetol Metab Syndr.,2012

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin;Diabetes Care;2024-04-23

2. A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial;International Journal of Diabetes in Developing Countries;2024-02-17

3. A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study);Journal of Diabetes Research;2024-01-05

4. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials;Endocrine Practice;2023-07

5. Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases;Nature Reviews Endocrinology;2023-03-17